The Size of the Asia Pacific Antibody Drug Conjugates Market is valued at USD 1.95 billion in 2021 and poised to grow at a CAGR of 28.56%, to reach USD 6.86 billion by 2026 during the forecast period 2021 to 2026.
An antibody-drug conjugate(ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of the biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduce the risk of developing treatment resistant disorders in the body.
By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi, and viruses in the body. Antibody-drug conjugates are widely accepting by several small and big pharmaceutical companies that are filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging, and vaccines.
Factors like rising in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer-killing ability and research development of ADCs, growing biomedical industry, new product innovations, and technological advancements are driving the Asia-Pacific Antibody Drug Conjugates Market. However, the high cost of production of ADCs and stringent regulations for product approval are hindering the growth of the market.
Asia Pacific Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories
On the basis of region, the Asia-Pacific is the fastest-growing region with a high CAGR owing to the rise in prevalence of cancer, growing demographics and emerging economies like China and India.
Top Companies dominating the Asia Pacific Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pipeline Analysis
5.1.1 Introduction
5.1.2 Phase
5.1.3 Mode of action
5.1.3.1 IgG1 antibodies
5.1.3.2 HER2 antibodies
5.1.4 Technology
5.1.4.1 Seattle Genetics
5.1.4.2 Immunogen
5.1.4.3 Immunomedics
5.1.5 Linker
5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis
5.1.7 Market Attractiveness Analysis, By Pipeline Analysis
5.1.8 Market Share Analysis, By Pipeline Analysis
5.2 End-user
5.2.1 Introduction
5.2.2 Research institutes
5.2.3 Hospitals
5.2.4 Clinics
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pipeline Analysis
6.1.3.3 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pipeline Analysis
6.1.4.3 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pipeline Analysis
6.1.5.3 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Seattle Genetics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Genentech
8.3 Takeda Pharmaceuticals
8.4 F. Hoffmann-La Roche
8.5 Bayer Healthcare
8.6 Agensys, Inc.,
8.7 Immunogen
8.8 Novartis
8.9 Oxford Biotherapeutics
8.10 Synthon Biopharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
